In Reply. (2nd November 2016)

• Record Type: Journal Article
• Authors: Brandi, Giovanni; Deserti, Marzia; Vasuri, Francesco; Farioli, Andrea; Degiovanni, Alessio; Palloni, Andrea; Frega, Giorgio; Barbera, Maria A.; de Lorenzo, Stefania; Garajova, Ingrid; Di Marco, Mariacristina; Pinna, Antonio D.; Cescon, Matteo; Cucchetti, Alessandro; Ercolani, Giorgio; D'Errico-Grigioni, Antonietta; Pantaleo, Maria A.; Biasco, Guido; Tavolari, Simona
• Other Names: Brandi Giovanni contributionsBy.; Aprile Giuseppe contributionsBy.; Cereda Stefano contributionsBy.; Fornaro Lorenzo contributionsBy.; Leone Francesco contributionsBy.; Lonardi Sara contributionsBy.; Santini Daniele contributionsBy.; Silvestris Nicola contributionsBy.; Vasile Enrico contributionsBy.
• Is Part Of: Oncologist. Volume 21:Number 12(2016)
• Page Start: e5
• Page End: e6
• Publication Date: 2016-11-02
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2016-0286
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.